Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 16/20 | 0.55 |
| ▸ | JAK3 | P52333 | 16/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 15/20 | 0.55 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21886917 | 0.89 | JAK3 (0.54) | JAK2JAK3PTK2JAK1PSEN1 | |
| SCHEMBL18636060 | 0.89 | JAK3 (0.54) | JAK2JAK3PTK2JAK1PSEN1 | |
| SCHEMBL18615092 | 0.89 | JAK3 (0.54) | JAK2JAK3PTK2JAK1PSEN1 | |
| SCHEMBL18615149 | 0.88 | JAK2 (0.47) | JAK2JAK3PTK2PSEN1PSEN2 | |
| SCHEMBL21887005 | 0.88 | JAK2 (0.47) | JAK2JAK3PTK2PSEN1PSEN2 | |
| SCHEMBL18636494 | 0.88 | JAK2 (0.47) | JAK2JAK3PTK2PSEN1PSEN2 | |
| SCHEMBL21887511 | 0.86 | PSEN1 (0.63) | JAK2JAK3PTK2PSEN1PSEN2 | |
| SCHEMBL18615145 | 0.86 | PSEN1 (0.63) | JAK2JAK3PTK2PSEN1PSEN2 | |
| SCHEMBL18614992 | 0.85 | JAK3 (0.52) | JAK2JAK3PTK2JAK1PSEN1 | |
| SCHEMBL21886844 | 0.85 | JAK3 (0.52) | JAK2JAK3PTK2JAK1PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604517-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604517-B2 | Bridged piperidine derivatives | HPGDS, APP, PSEN1 | JAK2 2869/4885JAK3 4320/4885PTK2 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.